Artificial intelligence-based cardiovascular/stroke risk stratification in women affected by autoimmune disorders: a narrative survey.

Journal: Rheumatology international
PMID:

Abstract

Women are disproportionately affected by chronic autoimmune diseases (AD) like systemic lupus erythematosus (SLE), scleroderma, rheumatoid arthritis (RA), and Sjögren's syndrome. Traditional evaluations often underestimate the associated cardiovascular disease (CVD) and stroke risk in women having AD. Vitamin D deficiency increases susceptibility to these conditions. CVD risk prediction in AD can benefit from surrogate biomarker for coronary artery disease (CAD), such as carotid ultrasound. Due to non-linearity in the CVD risk stratification, we use artificial intelligence-based system using AD biomarkers and carotid ultrasound. Investigate the relationship between AD and CVD/stroke markers including autoantibody-influenced plaque load. Second, to study the surrogate biomarkers for the CAD and gather radiomics-based features such as carotid intima-media thickness (cIMT), and plaque area (PA). Third and final, explore the automated CVD/stroke risk identification using advanced machine learning (ML) and deep learning (DL) paradigms. Analysed biomarker data from women with AD, including carotid ultrasonography imaging, clinical parameters, autoantibody profiles, and vitamin D levels. Proposed artificial intelligence (AI) models to predict CVD/stroke risk accurately in AD for women. There is a strong association between AD duration and elevated cIMT/PA, with increased CVD risk linked to higher rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs) levels. AI models outperformed conventional methods by integrating imaging data and disorder-specific factors. Interdisciplinary collaboration is crucial for managing CVD/stroke in women with chronic autoimmune diseases. AI-based assisted risk stratification methods may improve treatment decision-making and cardiovascular outcomes.

Authors

  • Ekta Tiwari
    Vishvswarya National Institute of Technology, Nagpur, India.
  • Dipti Shrimankar
    Vishvswarya National Institute of Technology, Nagpur, India.
  • Mahesh Maindarkar
    School of Bioengineering and Sciences and Research, MIT Art Design and Technology University, Pune, 4123018, India.
  • Mrinalini Bhagawati
    Department of Biomedical Engineering, North-Eastern Hill University, Shillong, India.
  • Jiah Kaur
    Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, 95661, USA.
  • Inder M Singh
    Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, 95747, CA, USA.
  • Laura Mantella
    Division of Cardiology, Department of Medicine, University of Toronto, Toronto, Canada.
  • Amer M Johri
    Division of Cardiology, Department of Medicine, Queen's University, Kingston, ON, Canada.
  • Narendra N Khanna
    Cardiology Department, Apollo Hospitals, New Delhi, India.
  • Rajesh Singh
    Division of Research and Innovation, UTI, Uttaranchal University, Dehradun, India.
  • Sumit Chaudhary
    Department of Research and Innovation, UIT, Uttaranchal University, Dehradun, 248007, India.
  • Luca Saba
    Department of Radiology, A.O.U., Italy.
  • Mustafa Al-Maini
    Allergy, Clinical Immunology and Rheumatology Institute, M3H 6A7, Toronto, Canada.
  • Vinod Anand
    Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, 95661, USA.
  • George Kitas
    Academic Affairs, Dudley Group NHS Foundation Trust, Dudley, DY1 2HQ, UK.
  • Jasjit S Suri
    Advanced Knowledge Engineering Center, Global Biomedical Technologies, Inc., Roseville, CA, USA. Electronic address: jsuri@comcast.net.